Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 1413-1424

  Singh, Dave ^a   Maleki Yazdi, M Reza ^b   Tombs, Lee ^c   Iqbal, Ahmar ^d   Fahy, William A ^e   Naya, Ian ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c Precise Approach LTD   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Airway stability; COPD; Deterioration; UMEC VI

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE; UMECLIDINIUM PLUS VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILAT; CHLOROBENZENE; DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENETHYLAMINE DERIVATIVE; PROPYLAMINE; QUINUCLIDINE DERIVATIVE; UMECLIDINIUM; VILANTEROL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG EFFECTS; HEALTH STATUS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SPIROMETRY; TIME FACTOR; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BENZYL ALCOHOLS; CHLOROBENZENES; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; LUNG; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MUSCARINIC ANTAGONISTS; PHENETHYLAMINES; PROPYLAMINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84976610888     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S101612     Document Type: Article

References (27)

1. GOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2015. Available from: http://www.goldcopd.com/. Accessed August 12, 2015.
2. Dransfield MT, Bailey W, Crater G, Emmett A, O’Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20(1):46-53.
3. Singh D. New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol. 2015;79(5):695-708.
4. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538-1546.
5. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981-991.
6. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752-1760.
7. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15-25.
8. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472-486.
9. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-1494.
10. Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med. 2015;109(9):1155-1163.
11. Jones PW. St George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-79.
12. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
13. Schmidt SA, Johansen MB, Olsen M, et al. The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study. BMJ Open. 2014;4(12): e006720.
14. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8-11.
15. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952-1959.
16. Tockman MS, Pearson JD, Fleg JL, et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med. 1995;151(2 Pt 1):390-398.
17. Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44(5):1156-1165.
18. Wilke S, Jones PW, Mullerova H, et al. One-year change in health status and subsequent outcomes in COPD. Thorax. 2015;70(5):420-425.
19. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111-124.
20. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
21. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
22. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267-272.
23. Garcia-Rio F, Rojo B, Casitas R, et al. Prognostic value of the objective measurement of daily physical activity in patients with COPD. Chest. 2012;142(2):338-346.
24. Vaes AW, Garcia-Aymerich J, Marott JL, et al. Changes in physical activity and all-cause mortality in COPD. Eur Respir J. 2014;44(5):1199-1209.
25. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106(4):522-530.
26. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33(2):262-272.
27. Singh D, Zhu CQ, Sharma S, Church A, Kalberg CJ. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study. Pulm Pharmacol Ther. 2015;31:85-91.